Low protective PON1 lactonase activity in an Arab population with high rates of coronary heart disease and diabetes

Clinica Chimica Acta

Volumn 445, Issue , 2015, Pages 41-47

  Gugliucci, A ^a   Caccavello, R ^a   Nassar, H ^b,c   Ahmad, W Abu ^d   Sinnreich, R ^d   Kark, J D ^d  

^a Touro University California   (United States)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^c St Joseph's Hospital   (Israel)

^d HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Cardiovascular risk; High density lipoprotein; Jewish; Lactonase; Palestinians; PON1

Indexed keywords

ARYLDIALKYLPHOSPHATASE; ARYLDIALKYLPHOSPHATASE 1; ARYLESTERASE; CHOLESTEROL; GLUCONOLACTONASE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; CARBOXYLESTERASE; GLUCOSE BLOOD LEVEL; PON1 PROTEIN, HUMAN;

ADULT; ARAB; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; DIET RESTRICTION; ENZYME ACTIVITY; FEMALE; GENE FREQUENCY; GENOTYPE; HUMAN; ISCHEMIC HEART DISEASE; ISRAEL; ISRAELI; JEW; MAJOR CLINICAL STUDY; MALE; OBESITY; PALESTINIAN; POPULATION RESEARCH; PREVALENCE; PRIORITY JOURNAL; AGE; AGED; ALLELE; BLOOD; CORONARY DISEASE; ENZYMOLOGY; EPIDEMIOLOGY; ETHNOLOGY; GENE EXPRESSION; GENETICS; GLUCOSE BLOOD LEVEL; METABOLISM; MIDDLE AGED; RISK FACTOR;

ADULT; AGE FACTORS; AGED; ALLELES; ARABS; ARYLDIALKYLPHOSPHATASE; BLOOD GLUCOSE; CARBOXYLIC ESTER HYDROLASES; CHOLESTEROL, HDL; CORONARY DISEASE; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS; FEMALE; GENE EXPRESSION; GENE FREQUENCY; GENOTYPE; HUMANS; ISRAEL; JEWS; MALE; MIDDLE AGED; OBESITY; PREVALENCE; RISK FACTORS; TRIGLYCERIDES;

EID: 84925424571     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2015.03.012     Document Type: Article

References (42)

1. Kark J.D., Fink R., Adler B., Goldberger N., Goldman S. The incidence of coronary heart disease among Palestinians and Israelis in Jerusalem. Int J Epidemiol 2006, 35:448-457.
2. Kark J.D., Gordon E.S., Haklai Z. Coronary heart disease mortality among Arab and Jewish residents of Jerusalem. Lancet 2000, 356:1410-1411.
3. Israel Center for Disease Control, Israel Ministry of Health. The State of Health of the Arab Population 2004, 2005 (Publication No. 226) (Hebrew).
4. Kalter-Leibovici O., Chetrit A., Lubin F., Atamna A., Alpert G., Ziv A., et al. Adult-onset diabetes among Arabs and Jews in Israel: a population-based study. Diabet Med 2012, 29:748-754.
5. Abdul-Rahim H.F., Husseini A., Bjertness E., Giacaman R., Gordon N.H., Jervell J. The metabolic syndrome in the West Bank population: an urban-rural comparison. Diabetes Care 2001, 24:275-279.
6. Voight B.F., Peloso G.M., Orho-Melander M., Frikke-Schmidt R., Barbalic M., Jensen M.K., et al. Plasma HDL cholesterol and risk of myocardial infarction: a Mendelian randomisation study. Lancet 2012, 380:572-580.
7. Boden W.E., Probstfield J.L., Anderson T., Chaitman B.R., Desvignes-Nickens P., et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011, 365:2255-2267.
8. Kontush A. HDL-mediated mechanisms of protection in cardiovascular disease. Cardiovasc Res 2014, 103:341-349.
9. Mackness B., Durrington P.N., Abuashia B., Boulton A.J., Mackness M.I. Low paraoxonase activity in type II diabetes mellitus complicated by retinopathy. Clin Sci 2000, 98:355-363.
10. Huang Y., Wu Z., Riwanto M., Gao S., Levison B.S., Gu X., et al. Myeloperoxidase, paraoxonase-1, and HDL form a functional ternary complex. J Clin Invest 2013, 123:3815-3828.
11. Aviram M., Vaya J. Paraoxonase 1 activities, regulation, and interactions with atherosclerotic lesion. Curr Opin Lipidol 2013, 24:339-344.
12. Camps J., Marsillach J., Joven J. The paraoxonases: role in human diseases and methodological difficulties in measurement. Crit Rev Clin Lab Sci 2009, 46:83-106.
13. Bar-Rogovsky H., Hugenmatter A., Tawfik D.S. The evolutionary origins of detoxifying enzymes: the mammalian serum paraoxonases (PONs) relate to bacterial homoserine lactonases. J Biol Chem 2013, 288:23914-23927.
14. Mueller R.F., Hornung S., Furlong C.E., Anderson J., Giblett E.R., Motulsky A.G. Plasma paraoxonase polymorphism: a new enzyme assay, population, family, biochemical, and linkage studies. Am J Hum Genet 1983, 35:393-408.
15. Richter R.J., Jarvik G.P., Furlong C.E. Paraoxonase 1 status as a risk factor for disease or exposure. Adv Exp Med Biol 2010, 660:29-35.
16. Draganov D.I. Lactonases with organophosphatase activity: structural and evolutionary perspectives. Chem Biol Interact 2010, 187:370-372.
17. Rainwater D.L., Rutherford S., Dyer T.D., Rainwater E.D., Cole S.A., Vandeberg J.L., et al. Determinants of variation in human serum paraoxonase activity. Heredity 2009, 102:147-154.
18. Merom D., Sinnreich R., Aboudi V., Kark J.D., Nassar H. Lifestyle physical activity among urban Palestinians and Israelis: a cross-sectional comparison in the Palestinian-Israeli Jerusalem risk factor study. BMC Public Health 2012, 12:90.
19. Kark J.D., Nassar H., Shaham D., Sinnreich R., Goldberger N., Aboudi V., et al. Leukocyte telomere length and coronary artery calcification in Palestinians. Atherosclerosis 2013, 229:363-368.
20. Gugliucci A. Activation of paraoxonase 1 is associated with HDL remodeling ex vivo. Clin Chim Acta 2014, 429:38-45.
21. Gugliucci A., Caccavello R., Kotani K., Sakane N., Kimura S. Enzymatic assessment of paraoxonase 1 activity on HDL subclasses: a practical zymogram method to assess hdl function. Clin Chim Acta 2013, 415:162-168.
22. Jabara R., Namouz S., Kark J.D., Lotan C. Risk characteristics of Arab and Jewish women with coronary heart disease in Jerusalem. Isr Med Assoc J IMAJ 2007, 9:316-320.
23. Weiss R., Nassar H., Sinnreich R., Kark J.D. Differences in the triglyceride to HDL cholesterol ratio between Palestinian and Israeli adults. PLoS One 2015, 10(1):e0116617. 10.1371/journal.pone.0116617.
24. Tang W.H., Hartiala J., Fan Y., Wu Y., Stewart A.F., Erdmann J., et al. Clinical and genetic association of serum paraoxonase and arylesterase activities with cardiovascular risk. Arterioscler Thromb Vasc 2012, 32:2803-2812.
25. Feig J.E., Hewing B., Smith J.D., Hazen S.L., Fisher E.A. High-density lipoprotein and atherosclerosis regression: evidence from preclinical and clinical studies. Circ Res 2014, 114:205-213.
26. Costa L.G., Giordano G., Furlong C.E. Pharmacological and dietary modulators of paraoxonase 1 (PON1) activity and expression: the hunt goes on. Biochem Pharmacol 2011, 81:337-344.
27. Camont L., Lhomme M., Rached F., Le Goff W., Negre-Salvayre A., Salvayre R., et al. Small, dense high-density lipoprotein-3 particles are enriched in negatively charged phospholipids: relevance to cellular cholesterol efflux, antioxidative, antithrombotic, anti-inflammatory, and antiapoptotic functionalities. Arterioscler Thromb Vasc 2013, 33:2715-2723.
28. Camont L., Chapman M.J., Kontush A. Biological activities of HDL subpopulations and their relevance to cardiovascular disease. Trends Mol Med 2011, 17:594-603.
29. Kotani K., Sakane N., Sano Y., Tsuzaki K., Matsuoka Y., Egawa K., et al. Changes on the physiological lactonase activity of serum paraoxonase 1 by a diet intervention for weight loss in healthy overweight and obese women. J Clin Biochem Nutr 2009, 45:329-334.
30. Grubisa I., Otasevic P., Dimkovic N., Nedeljkovic I., Toljic B., Vucinic N. Genetic polymorphisms of paraoxonase 1 and susceptibility to atherogenesis. Srp Arh Celok Lek 2013, 141:629-633.
31. Lawlor D.A., Day I.N., Gaunt T.R., Hinks L.J., Briggs P.J., Kiessling M., et al. The association of the PON1 q192r polymorphism with coronary heart disease: findings from the British Women's Heart and Health Cohort Study and a meta-analysis. BMC Genet 2004, 5:17.
32. Brophy V.H., Jarvik G.P., Richter R.J., Rozek L.S., Schellenberg G.D., Furlong C.E. Analysis of paraoxonase (PON1) l55m status requires both genotype and phenotype. Pharmacogenetics 2000, 10:453-460.
33. Kim D.S., Maden S.K., Burt A.A., Ranchalis J.E., Furlong C.E., Jarvik G.P. Dietary fatty acid intake is associated with paraoxonase 1 activity in a cohort-based analysis of 1,548 subjects. Lipids Health Dis 2013, 12:183.
34. Kim D.S., Burt A.A., Ranchalis J.E., Richter R.J., Marshall J.K., Nakayama K.S., et al. Dietary cholesterol increases paraoxonase 1 enzyme activity. J Lipid Res 2012, 53:2450-2458.
35. Boshtam M., Razavi A.E., Pourfarzam M., Ani M., Naderi G.A., Basati G., et al. Serum paraoxonase 1 activity is associated with fatty acid composition of high density lipoprotein. Dis Markers 2013, 35:273-280.
36. Arunima S., Rajamohan T. Effect of virgin coconut oil enriched diet on the antioxidant status and paraoxonase 1 activity in ameliorating the oxidative stress in rats - a comparative study. Food Funct 2013, 4:1402-1409.
37. Schrader C., Rimbach G. Determinants of paraoxonase 1 status: genes, drugs and nutrition. Curr Med Chem 2011, 18:5624-5643.
38. Cohen E., Aviram M., Khatib S., Artul F., Rabin A., Mannheim D., et al. Human carotid plaque phosphatidyl choline (PC), specifically interacts with paraoxonase1 (PON1), increases its activity and enhances its uptake by macrophage at the expense of its binding to HDL. Free Radic Biol Med 2014, 76:14-24.
39. Rosenblat M., Ward S., Volkova N., Hayek T., Aviram M. VLDL triglycerides inhibit HDL-associated paraoxonase 1 (PON1) activity: in vitro and in vivo studies. Biofactors 2012, 38:292-299.
40. Abu-Saad K., Murad H., Lubin F., Freedman L.S., Ziv A., Alpert G., et al. Jews and Arabs in the same region in Israel exhibit major differences in dietary patterns. J Nutr 2012, 142:2175-2181.
41. Mackness B., Durrington P.N., Boulton A.J., Hine D., Mackness M.I. Serum paraoxonase activity in patients with type 1 diabetes compared to healthy controls. Eur J Clin Invest 2002, 32:259-264.
42. Ostrer H., Skorecki K. The population genetics of the Jewish people. Hum Genet 2013, 132:119-127.